1. Home
  2. PHVS vs NN Comparison

PHVS vs NN Comparison

Compare PHVS & NN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • NN
  • Stock Information
  • Founded
  • PHVS 2015
  • NN 2007
  • Country
  • PHVS Switzerland
  • NN United States
  • Employees
  • PHVS N/A
  • NN N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • NN Industrial Machinery/Components
  • Sector
  • PHVS Health Care
  • NN Industrials
  • Exchange
  • PHVS Nasdaq
  • NN Nasdaq
  • Market Cap
  • PHVS 980.3M
  • NN 1.8B
  • IPO Year
  • PHVS 2021
  • NN N/A
  • Fundamental
  • Price
  • PHVS $17.07
  • NN $15.14
  • Analyst Decision
  • PHVS Buy
  • NN
  • Analyst Count
  • PHVS 6
  • NN 0
  • Target Price
  • PHVS $37.17
  • NN N/A
  • AVG Volume (30 Days)
  • PHVS 54.0K
  • NN 1.4M
  • Earning Date
  • PHVS 08-13-2025
  • NN 08-06-2025
  • Dividend Yield
  • PHVS N/A
  • NN N/A
  • EPS Growth
  • PHVS N/A
  • NN N/A
  • EPS
  • PHVS N/A
  • NN N/A
  • Revenue
  • PHVS N/A
  • NN $6,162,000.00
  • Revenue This Year
  • PHVS N/A
  • NN $18.26
  • Revenue Next Year
  • PHVS N/A
  • NN $4.59
  • P/E Ratio
  • PHVS N/A
  • NN N/A
  • Revenue Growth
  • PHVS N/A
  • NN 51.10
  • 52 Week Low
  • PHVS $11.51
  • NN $6.47
  • 52 Week High
  • PHVS $25.50
  • NN $18.54
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 50.14
  • NN 70.01
  • Support Level
  • PHVS $16.78
  • NN $14.57
  • Resistance Level
  • PHVS $17.53
  • NN $15.54
  • Average True Range (ATR)
  • PHVS 1.09
  • NN 0.84
  • MACD
  • PHVS 0.00
  • NN 0.22
  • Stochastic Oscillator
  • PHVS 29.50
  • NN 87.47

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About NN NextNav Inc.

NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.

Share on Social Networks: